Lao People's Democratic Republic vs Naoero: Hepatitis B surface antigen (HBsAg) prevalence
Lao People's Democratic Republic
0.6%
in 2024
Naoero
0.6%
in 2024
Lao People's Democratic Republic rank
51st
Naoero rank
51st
Hepatitis B surface antigen (HBsAg) prevalence over time
- Lao People's Democratic Republic
- Naoero
How they compare
Lao People's Democratic Republic currently reports 0.6% against 0.6% in Naoero, a difference of 0.0%.
The two have swapped places 3 times across 10 shared years of data; in 2015 it was Lao People's Democratic Republic ahead.
Lao People's Democratic Republic ranks 51st and Naoero ranks 51st of 194 countries.
Lao People's Democratic Republic has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Lao People's Democratic Republic | Naoero | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1.3% | 1.2% | 0.1% | Lao People's Democratic Republic |
| 2020s | 0.7% | 0.7% | 0.0% | Lao People's Democratic Republic |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hepatitis b surface antigen (hbsag) prevalence, Lao People's Democratic Republic or Naoero?
- Lao People's Democratic Republic, at 0.6% against 0.6% in Naoero as of 2024.
- What is the difference in hepatitis b surface antigen (hbsag) prevalence between Lao People's Democratic Republic and Naoero?
- 0.0%, with Lao People's Democratic Republic ahead.
- How many years of comparable data are there for Lao People's Democratic Republic and Naoero?
- 10 years are reported by both, from 2015 to 2024.
- How do Lao People's Democratic Republic and Naoero rank globally for hepatitis b surface antigen (hbsag) prevalence?
- Lao People's Democratic Republic ranks 51st and Naoero ranks 51st of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hepatitis B surface antigen (HBsAg) prevalence (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.